Palmitoylethanolamide (PEA) is produced by mammalian cells from its biosynthetic
precursor, N-palmitoyl-phosphatidyl-ethanolamine, and inactivated by enzymatic hydrolysis …

N-Acylethanolamine acid amidase (NAAA) is a cysteine amidase that hydrolyzes saturated
or monounsaturated fatty acid ethanolamides, such as palmitoylethanolamide (PEA) and …

Although its presence in mammalian tissues has been known since the 1960s, N-palmitoyl-
ethanolamine (PEA) has emerged only recently among other bioactive N-acylethanolamines …

Highlights•PEA is an anti-inflammatory and neuroprotective compound.•Pharmacological
tools are available to control PEA levels via FAAH and NAAA inhibition.•FAAH and NAAA …

Identifying points of control in inflammation is essential to discovering safe and effective
antiinflammatory medicines. Palmitoylethanolamide (PEA) is a naturally occurring lipid …

Fatty acid ethanolamides (FAEs), which include palmitoylethanolamide (PEA) and
oleoylethanolamide (OEA), are endogenous agonists of peroxisome proliferator-activated …

Exogenous cannabinoid receptor agonists are clinically effective for treating chronic pain but
frequently cause side effects in the central nervous system. Fatty acid amide hydrolase …

N‐Acylethanolamine acid amidase (NAAA) is a cysteine hydrolase that catalyzes the
hydrolysis of endogenous lipid mediators such as palmitoylethanolamide (PEA). PEA has …

N-acylethanolamines (NAEs) involve a family of lipid molecules existent in animal and plant,
with N-palmitoylethanolamide (PEA) that arouses great attention owing to its anti …

Persistent pain affects nearly half of all people seeking medical care in the US alone, and
accounts for at least $80 billion worth of lost productivity each year. Among all types of …